Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales

Biogen’s Byooviz Biosimilar Launched 1 July; Company Stressed Gradual Launch

Executive Summary

With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.

You may also be interested in...



Samsung Bioepis Launches Ranibizumab In Korea

Samsung Bioepis has announced the launch of its SB11 ranibizumab biosimilar rival to Lucentis in Korea through partner Samil. The introduction – under the name Amelivu – comes after the product was launched as Byooviz in the US last year.

Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar

Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.

US Tocilizumab Race Heats Up As Biogen Matches Kabi’s Filing

In a small pool of developers, Biogen has matched Fresenius Kabi by filing its proposed tocilizumab biosimilar with the US Food and Drug Administration.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel